Ethyl 4-methyl -5-{2-(trifluoromethyl) phenyl} 1H-pyrrole -3-carboxylate, CAS 1631030-76-6, purity ≥ 98%, is a key pyrrole intermediate in the synthesis of drugs such as oxalone. Relying on customized synthesis platform and strict quality control system, Shanghai Lizhuo Pharmaceutical provides stable supply from gram to kilogram and ton for global pharmaceutical enterprises. Please contact us for cooperation.
List of product parameters
| Name | Ethyl 4-methyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxylate |
| Alias | 4-Methyl -5-[2-(trifluoromethyl) phenyl]-1H-pyrrole-3-carboxylic acid ethyl ester; 1H-pyrrole-3-carboxylic acid, 4-methyl -5-[2-(trifluoromethyl) phenyl]-, ethyl ester |
| CAS No. | 1631030-76-6 |
| chemical formula | C₁₅H₁₄F₃NO₂ |
| molecular weight | 297.27 |
| InChI | InChI=1S/C15H14F3NO2/c1-3-21-14(20)11-8-19-13(9(11)2)10-6-4-5-7-12(10)15(16,17)18/h4-8,19H,3H2,1-2H3 |
| density | 1.253±0.06g/cm³ (predicted) |
| boiling Point | 420.5±45.0°C (predicted) |
| storage conditions | sealed, dry, 2-8°C |
| specific Gravity | approximately 1.253 (same density, predicted) |
| dangerous Goods Signs | GHS07 (Warning) |
| risk Terms | H302 (harmful if swallowed), H315 (causing skin irritation), H319 (causing severe eye irritation), H335 (may cause respiratory irritation) |
| safety terminology | p261, P305 + P351 + P338 (as per GHS General Precautionary Instructions) |
| customs Number | 29339990 (pyrrole derivatives, subject to actual declaration) |
nature
the compound is a derivative of ethyl pyrrole carboxylate containing trifluoromethyl substituted phenyl group, and there are pyrrole NH, ester group and strong electron withdrawing CF group in the molecule. The predicted density is about 1.253g/cm³, and the predicted boiling point is about 420.5°C, indicating a higher molecular weight and lower volatility. Storage requires sealing, drying, and low temperature (2-8°C) to maintain the stability of the ester group and the pyrrole ring.
Use
the core application is pharmaceutical intermediates, especially as a key pyrrole building block in the synthetic route of selective mineralocorticoid receptor antagonists such as Esaxerenone. In addition, the pyrrole carboxylic acid ester skeleton can also be used for the structural modification of other active molecules containing pyrrole and the synthesis of library compounds, which is suitable for the early stage of innovative drug research and development to the process scale-up stage.
Safety Information
the GHS is classified as a warning (Warning) and hazard statements include H302 (Harmful if swallowed), H315 (Skin Irritation), H319 (Severe Eye Irritation), and H335 (Respiratory Irritation). The operation should be carried out in the fume hood, wear protective gloves, goggles and dust mask, avoid inhaling dust or vapor, and avoid direct contact with skin and eyes. The specific safety data shall be based on the MSDS provided by the supplier.
Why Choose Shanghai Lizhuo Pharmaceutical? — Company Advantage and Capacity
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. (Shanghai Lizhuo Pharmaceutical Technology Co., Ltd.) is a subsidiary of Shenzhen Ruiqi Chemical Technology Co., Ltd. It is committed to providing global pharmaceutical enterprises and new drug research and development institutions with pharmaceutical intermediate research and development and customized production services throughout the life cycle from early clinical research to drug listing.
core advantages and competitiveness:
1.
Customized synthesis capability covers the whole cycle: from gram-level route screening to kilogram-level and ton-level process amplification, the batch can be flexibly adjusted according to customer needs, and the customized synthesis and process optimization of non-standard intermediates can be undertaken.
2.
The quality system runs through the whole process: the internal control standard of purity ≥ 98% is implemented for key intermediates, and the quality system has complete COA, MSDS and batch traceability capabilities to meet the strict requirements of pharmaceutical customers for impurity spectrum and batch consistency.
3.
The supply chain is stable and controllable: relying on the parent company’s resource accumulation and independent production platform in the chemical field, the key steps do not rely on outsourcing, reduce the risk of supply interruption, and ensure the continuity of the project from research and development to commercialization.
4.
Fast technical response: For popular target-related intermediates such as isalidone, with mature process knowledge, route evaluation, sample delivery and scale-up verification can be completed in a short period of time.
5.
Compliance and documentation support: Provide process descriptions, impurity studies and stability data frameworks that meet the audit requirements of pharmaceutical companies to assist customers in accelerating the preparation of intermediates in IND/NDA filings.
6.
Capacity Description: This product belongs to the conventional controllable scale in the company’s customized synthetic product sequence, and can be flexibly scheduled in several kilograms to 100 kilograms according to the order quantity. The specific ton-level supply needs to be combined with the process route evaluation and scheduling confirmation. Direct communication on the target quantity and delivery cycle is welcome.
5 Frequently Asked Questions about Home Buying
q1: Are you the manufacturer or trader of this product? Can you provide customized synthesis? A: Shanghai Lizhuo Pharmaceutical takes customized R & D and production as its core mode, has independent process development and amplification capabilities, and can provide customized synthesis services from gram to ton according to the customer’s target structure or specified route, rather than simple trade resale.
Q2: What is the purity of CAS 1631030-76-6? Do you have COA and MSDS? A: Conventional supply purity ≥ 98% (HPLC), COA is provided with each batch; MSDS can be provided according to customer requirements. If there are special impurity control requirements (such as specific single impurity limits, residual solvents, heavy metals, etc.), the test items can be agreed in the customized contract.
Q3: What drugs is this product mainly used for? Do you have relevant experience? A: This intermediate is a key building block in the synthesis of Esaxerenone and similar pyrrole skeleton drugs. The company has accumulated technology in the process development of pyrrole and fluorine-containing aromatic intermediates, and is able to provide suitable intermediate specifications for the coupling, esterification, ring-closing and other steps of the downstream route.
Q4: What is the minimum order quantity and delivery cycle? A: Samples from gram to 100 grams can usually be delivered within 1-2 weeks (depending on inventory and purity requirements); Batch quantities of kilogram and above shall be confirmed in combination with process scheduling, which is generally completed within 3-6 weeks after the contract is signed. Please provide the target quantity, purity specification and destination in order to give accurate delivery and logistics plan.
Q5: Can you provide regulatory supporting documentation, such as residual solvents, elemental impurities or stability data? A: Yes. According to the customer’s clinical stage and reporting requirements, the company can provide residual solvent testing, elemental impurity risk assessment framework, mandatory degradation/stability study program and other documentation packages to assist customers in the pharmaceutical and regulatory preparation of the intermediates section.
Welcome to visit our official website to learn more about product lines and customized synthesis services: https://www.shlzpharma.com/
if you need to obtain real-time quotation, COA sample or customized synthesis scheme of ethyl 4-methyl -5-{2-(trifluoromethyl) phenyl} 1H-pyrrole -3-carboxylate, please contact Shanghai Lizhuo Pharmaceutical Team directly through official website.
Post time: Nov-16-2026
